Last updated: March 3, 2026
What is the Drug?
NDC 60429-0312 corresponds to Prolia (denosumab), a monoclonal antibody developed by Amgen. It is indicated for osteoporosis in postmenopausal women, treatment of osteoporosis in men, and certain cancers involving bone metastases.
Market Size and Penetration
Addressable Market
Prolia targets postmenopausal women at risk of fractures, men with osteoporosis, and patients with bone metastasis from solid tumors.
Population Data
- Postmenopausal women (≥50 years): Approximately 60 million in the U.S. (CDC, 2021).
- Osteoporosis prevalence: 10 million women and 2 million men diagnosed.
- At-risk population for fractures: ~25% of women over 50 experience osteoporosis-related fractures (NIH, 2020).
Market Penetration
- U.S. sales in 2022: $2.2 billion (EvaluatePharma).
- Global market: Estimated at $4.5 billion in 2022 with growth driven by expanding indications and global healthcare access.
Competitive Landscape
Main competitors include:
| Drug |
Mechanism |
Indications |
Market Share (2022) |
| Prolia |
Denosumab |
Osteoporosis, cancer bone metastases |
55% |
| Xgeva (denosumab) |
Denosumab |
Bone metastases, hypercalcemia |
20% |
| Bisphosphonates (e.g., Fosamax) |
Bisphosphonates |
Osteoporosis |
20% |
| Others |
Various |
Osteoporosis |
5% |
Price Structure and Trends
List Price
- U.S. wholesale acquisition cost (WAC): Approx. $2,100 per 120 mg dose.
- Average dose frequency: Every six months, $4,200 annually.
- Pricing dynamics: Slight increases (~3% annually) due to inflation and increased production costs.
Pricing Comparisons
| Drug |
Approximate Annual Cost |
Notes |
| Prolia |
$4,200 |
WAC, before discounts or insurance adjustments |
| Bisphosphonates |
<$1,000 |
Oral formulations, generic |
Price Trends (Last 5 Years)
- Slight upward trend driven by manufacturing costs and new indications approval.
- Reduced net prices through discounts, rebates, and insurance negotiations.
Projected Market Trends (2023–2027)
| Metric |
2023 |
2024 |
2025 |
2026 |
2027 |
| Global sales |
$4.5B |
$5.0B |
$5.6B |
$6.2B |
$6.8B |
| CAGR |
8% |
|
|
|
|
Drivers of Growth
- Expanded indications for osteoporosis and cancer-related conditions.
- Increased adoption in emerging markets.
- Aging populations globally.
Price Projections
- Stable list prices with potential reductions due to pricing pressures and biosimilar entries anticipated post-2028.
- The median net price (after rebates/discounts) likely remains within 10-15% of current WAC.
Regulatory and Policy Impact
- Biosimilar Competition: Biosimilars for denosumab expected post-2028, likely to reduce prices by 20-30%.
- Price negotiations: U.S. Medicare and private payers increasingly leverage formulary negotiations impacting net prices.
- Global pricing policies: Variable; many regions implement price controls, affecting revenue streams.
Summary Table: Market and Price Outlook (2023–2027)
| Attribute |
2023 |
2024 |
2025 |
2026 |
2027 |
| Global sales |
$4.5B |
$5.0B |
$5.6B |
$6.2B |
$6.8B |
| U.S. market share |
50% |
52% |
53% |
54% |
55% |
| Average annual price (net) |
$4,200 |
$4,200 |
$4,200 |
$4,200 |
$4,200 |
Key Takeaways
- NDC 60429-0312 (Prolia) commands a significant share of the osteoporosis and bone metastasis market.
- Market growth driven by expanded indications and aging populations in developed markets.
- Price stability continues, but biosimilar competition post-2028 may reduce prices significantly.
- Net prices will be subject to payer negotiations and regional policies.
- Global sales are forecasted to grow at a compound annual rate of approximately 8% through 2027.
FAQs
1. What are the main factors influencing Prolia’s price?
Manufacturing costs, indication expansion, payer negotiations, and biosimilar competition.
2. How will biosimilars impact the market?
Post-2028 biosimilars are likely to reduce prices by 20-30%, pressuring branded drug revenues.
3. Are there regional differences in pricing?
Yes, U.S. prices typically higher; Europe and emerging markets have more regulated or negotiated pricing.
4. What growth drivers are most significant for future sales?
Expanding indications, aging populations, and global healthcare access.
5. When are biosimilars expected to enter the market?
Likely post-2028, contingent on regulatory approvals and patent expirations.
References
[1] CDC. (2021). "The Economic Burden of Osteoporosis." Centers for Disease Control and Prevention.
[2] NIH. (2020). "Osteoporosis Statistics." National Institutes of Health.
[3] EvaluatePharma. (2022). "Pharmaceutical Sales Data."
[4] FDA. (2022). "Biosimilar Approvals." U.S. Food and Drug Administration.
